RxDoctor Payments Data

Melissa Halverson, NP

Nurse Practitioner · Chicago, ILNPI 1558887174

Payments from drug & device makers

$4,301in general payments, 2019–2025

Across 245 payments — averaging $17.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Regeneron Healthcare Solutions, Inc.$475
  • Takeda Pharmaceuticals U.S.A., Inc.$442
  • Johnson & Johnson$433
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$409
  • Lilly USA, LLC$188
  • plus $1K from 20 others

What the payments were for

  • Food & beverage$4,18297%
  • Education$1193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,301 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$35,881
Medicare patients
271
Services billed
425

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab12$330,786
CreonLipase/Protease/Amylase25$75,429
XifaxanRifaximin24$71,039
ZenpepLipase/Protease/Amylase15$44,463
TrulancePlecanatide56$41,775
LinzessLinaclotide51$34,567
MovantikNaloxegol Oxalate24$11,563
Mesalamine ErMesalamine18$6,088
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates89$5,835
Dexlansoprazole DrDexlansoprazole19$5,404
Ursodiol17$3,849
Mesalamine22$2,864
Colestipol Hcl21$2,688
Omeprazole188$2,590
Pantoprazole Sodium207$2,433

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$433$330,78612 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$409$112,81480 claims
AbbVieCreon, Linzess$1,016$109,99676 claims
Aimmune Therapeutics, Inc.Zenpep$14$44,46315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →